1004764-45-7

Upstream product

• 1004764-43-5 2-[4-(benzyloxy)phenyl][1,3]oxazolo[4,5-c]pyridine 
• 6320-39-4 3-aminopyridin-4-ol 
• 1486-51-7 p-(benzyloxy)benzoic acid 
• 1354910-39-6 2-[4-(benzyloxy)phenyl]-5-methyl[1 ,3]oxazolo[4,5-c]pyridin-5-ium iodide 

Downstream Products

• 1004764-46-8 4-(5-methyl-4, 5,6,7-tetrahydro[1,3]oxazolo[4,5-c]pyridin-2-yl)phenol 
• 1354910-16-9 2-(4-benzyloxy-phenyl)-4,5,6,7-tetrahydro-oxazolo[4,5-c]pyridine 
• 1354910-17-0 3-[2-(4-benzyloxy-phenyl)-4,5,6,7-tetrahydro-oxazolo[4,5-c]pyridine-5-yl]-2-methyl-propionic acid t-butyl ester 
• 1354906-88-9 3-[2-(4-benzyloxy-phenyl)-6,7-dihydro-4H-oxazolo[4,5-c]pyridine-5-yl]-2-methyl-propionic acid 

Relevant academic research and scientific papers

FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS

The present invention relates to a fused heterocyclic derivative of the formula (I) The variables R1-R4, z, A, Q, X and Y are as defined in the claims. The following heterocycles are exemplified substructures of formula (I): The compounds of formula (I) are modulators of the S1P receptor (Sphingosine-1-phosphate receptor), More specifically, they are agonists of S1P5. The compounds have therapeutic use in treatment of cognitive disorders, age-relate cognitive decline and dementia.

FUSED OXAZOLES and THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS

The present invention relates to compounds comprising fused oxazole or thiazole derivatives of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, wherein A is a cyclic amine which is linked to the propylene group via an amino nitrogen; B is selected from the group consisting of heteroaryl, 5-8-membered heterocycloalkyl, 5-8-membered cycloalkyl; X is either N or CH; Y is either O or S.